BIXT's logo.
Ticker Symbol: BIXT

Bioxytran Inc

Exchange: OTC MARKETS Country: US Currency: USD Asset Type: Common Stock CIK:0001445815

Company Profile

bioxytran, inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. the company's lead pharmaceutical drug candidate is bxt-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for the treatment of patients with ischemia of the brain resulting from a stroke or the blockage of the blood vessels to the brain. its products also include bxt-252, an injectable anti-necrosis drug to treat a wound that does not heal because limited amount of oxygen reaching the wound. the company was founded in 2017 and is headquartered in newton, massachusetts.

Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Standard Industrial Classification Code (SIC code): 5150
Address: 233 Needham St Ste 300
CEO: David Platt
  • Pharmaceuticals: Major
  • Health Technology


Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $0.17
Change: $0.00 ( 5.42%)
Days Range: $0.16 - $0.18
Beta: -
52wk. High: $1.05
52wk. Low: $0.12
Ytd. Change -57.27%
50 Day Moving Average: $0.17
200 Day Moving Average: $0.25
Shares Outstanding: 144355355


Market Cap: 2.6B
PE Ratio: -
EPS (TTM): 0


Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A